Summary: Evaluated ivabradine versus placebo in patients with coronary artery disease and left ventricular dysfunction (EF < 40%). The primary endpoint of composite cardiovascular death, MI or heart failure admission was not met. Secondary endpoints were met in the subgroup of patients with heart rate > 70 beats per minute including reduced coronary events (22%), fatal and nonfatal MI (36%) and coronary revascularization (30%).

Original Publication:

Lancet. 2008 Sep 6;372(9641):807-16. Epub 2008 Aug 29.

Lancet. 2008 Sep 6;372(9641):817-21. Epub 2008 Aug 29.

Eur Heart J. 2009 Oct;30(19):2337-45. Epub 2009 Aug 31.

Eponym: morBidity-mortality EvAlUaTion of the IF inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction trial